Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takero Shindo

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Immunological Medicine|July 28, 2020
Allelic polymorphisms of <i>KIRs</i> and antitumor immunity against chronic myeloid leukemiaTakero Shindo, Hiroshi Ureshino, Hiroto Kojima, et al.
Molecular Cancer Therapeutics|October 21, 2020
<i>HLA</i> Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaHiroshi Ureshino, Takero Shindo, Hidenori Tanaka, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2007
Altered homeostasis of CD4(+) memory T cells in allogeneic hematopoietic stem cell transplant recipients: chronic graft-versus-host disease enhances T cell differentiation and exhausts central memory T cell poolAkiko Fukunaga, Takayuki Ishikawa, Masako Kishihata, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 12, 2017
Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mgHidekazu Itamura, Yasushi Kubota, Takero Shindo, et al.
Cancer Science|May 12, 2025
Upregulation of YY1/EZH2 and MLH1 as Therapeutic Targets for Adult T-Cell Leukemia/LymphomaTakuya Shimizu, Takero Shindo, Hanako Ogawa, et al.
Oncology Letters|April 9, 2024
Successful treatment of severe splenic lymphoma‑associated hemophagocytic syndrome by splenectomy and subsequent chemotherapy: A case reportHideyuki Masui, Maki Shindo, Yuta Inoue, et al.
JCI Insight|October 5, 2016
The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effectsHidekazu Itamura, Takero Shindo, Isao Tawara, et al.
Blood|April 12, 2013
MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent mannerTakero Shindo, Tae Kon Kim, Cara L Benjamin, et al.
Internal Medicine (Tokyo, Japan)|September 16, 2016
Subdural Hematoma Associated with Dasatinib and Intrathecal Methotrexate Treatment in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaHiroshi Ureshino, Atsujiro Nishioka, Kensuke Kojima, et al.
Cancer Immunology Research|April 27, 2018
Allelic Polymorphisms of <i>KIR</i>s and <i>HLA</i>s Predict Favorable Responses to Tyrosine Kinase Inhibitors in CMLHiroshi Ureshino, Takero Shindo, Hiroto Kojima, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Immunological Medicine|July 28, 2020
Allelic polymorphisms of <i>KIRs</i> and antitumor immunity against chronic myeloid leukemiaTakero Shindo, Hiroshi Ureshino, Hiroto Kojima, et al.
Molecular Cancer Therapeutics|October 21, 2020
<i>HLA</i> Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaHiroshi Ureshino, Takero Shindo, Hidenori Tanaka, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2007
Altered homeostasis of CD4(+) memory T cells in allogeneic hematopoietic stem cell transplant recipients: chronic graft-versus-host disease enhances T cell differentiation and exhausts central memory T cell poolAkiko Fukunaga, Takayuki Ishikawa, Masako Kishihata, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 12, 2017
Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mgHidekazu Itamura, Yasushi Kubota, Takero Shindo, et al.
Cancer Science|May 12, 2025
Upregulation of YY1/EZH2 and MLH1 as Therapeutic Targets for Adult T-Cell Leukemia/LymphomaTakuya Shimizu, Takero Shindo, Hanako Ogawa, et al.
Oncology Letters|April 9, 2024
Successful treatment of severe splenic lymphoma‑associated hemophagocytic syndrome by splenectomy and subsequent chemotherapy: A case reportHideyuki Masui, Maki Shindo, Yuta Inoue, et al.
JCI Insight|October 5, 2016
The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effectsHidekazu Itamura, Takero Shindo, Isao Tawara, et al.
Blood|April 12, 2013
MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent mannerTakero Shindo, Tae Kon Kim, Cara L Benjamin, et al.
Internal Medicine (Tokyo, Japan)|September 16, 2016
Subdural Hematoma Associated with Dasatinib and Intrathecal Methotrexate Treatment in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaHiroshi Ureshino, Atsujiro Nishioka, Kensuke Kojima, et al.
Cancer Immunology Research|April 27, 2018
Allelic Polymorphisms of <i>KIR</i>s and <i>HLA</i>s Predict Favorable Responses to Tyrosine Kinase Inhibitors in CMLHiroshi Ureshino, Takero Shindo, Hiroto Kojima, et al.
Pageof 7